William Blair, a well-known equities research firm, has been busy issuing and reaffirming ratings for several companies. Recent reports cover AvePoint (AVPT), Biodesix (BDSX), Fortrea (FTRE), and Rocket Pharmaceuticals (RCKT). Let's take a closer look at the firm's latest assessments.
AvePoint: Outperform Reaffirmed
AvePoint (NASDAQ:AVPT) received a reaffirmation of its "outperform" rating from William Blair, according to RTT News. This positive sentiment aligns with a recent price target increase from The Goldman Sachs Group, who raised their target from $7.50 to $15.00. The "outperform" rating suggests that William Blair believes AvePoint's stock is likely to perform better than the average stock in its sector.
Biodesix: Another Outperform Rating
Biodesix (NASDAQ:BDSX) also received an "outperform" rating from William Blair. In addition to the rating, William Blair issued earnings per share (EPS) estimates for the company's upcoming quarters in 2026. The firm projects Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, and Q4 2026 earnings at ($0.03) EPS. These estimates provide investors with insights into William Blair's expectations for Biodesix's financial performance in the coming years.
Fortrea: Market Perform Maintained
Not all ratings were "outperform." William Blair reiterated a "market perform" rating for Fortrea (NASDAQ:FTRE), as reported by Benzinga. Alongside this rating, the firm issued an EPS estimate of $0.39 for Fortrea's Q4 2025 earnings. It is important to note that Baird R W recently downgraded shares of Fortrea. A "market perform" rating typically indicates that William Blair expects Fortrea's stock to perform in line with the overall market.
Rocket Pharmaceuticals: Q1 2026 Earnings Forecast
Turning to the biotechnology sector, William Blair issued its Q1 2026 EPS estimates for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT). Analyst S. Corwin forecasts a loss of ($0.27) per share for the quarter. This forecast provides investors with a glimpse into the firm's expectations for Rocket Pharmaceuticals' near-term profitability.
These recent reports from William Blair offer valuable insights for investors tracking these companies. It's important to remember that analyst ratings and estimates are just one factor to consider when making investment decisions. Investors should conduct their own thorough research and consider their individual investment goals and risk tolerance.